Related by context. Frequent words. (Click for all words.) 68 nephrotoxicity 65 receiving VELCADE 64 Dasatinib 64 laboratory abnormalities 63 renal toxicity 63 antitumor activity 63 virologic response 63 QTc prolongation 62 myelosuppression 62 chlorambucil 62 systemic absorption 62 xenograft models 62 corticosteroid therapy 61 mycophenolate mofetil 61 antibody titers 61 pharmacodynamic effects 61 heavily pretreated 61 demyelinating disease 61 systemic toxicity 61 dose limiting toxicities 61 elotuzumab 61 thromboembolic events 61 events SAEs 61 hydroxychloroquine 60 Natalizumab 60 hypomagnesemia 60 ximelagatran 60 docetaxel chemotherapy 60 cardiac toxicity 60 Traficet EN 60 coagulopathy 60 PREZISTA r 60 hepatotoxicity 60 platelet inhibition 60 complete remissions 60 severe renal impairment 60 SCH # 60 pharmacokinetic profiles 60 liposomal formulation 60 platelet reactivity 60 ganetespib 60 lymphopenia 59 tocilizumab 59 superficial bladder cancer 59 #ME# 59 Adalimumab 59 cytogenetic response 59 analgesic efficacy 59 CMV infection 59 tipranavir 59 clinically meaningful improvement 59 daunorubicin 59 limiting toxicity 59 tolerability profile 59 surrogate endpoint 59 azacitidine 59 tigecycline 59 neuropsychiatric symptoms 59 decitabine 59 fluvastatin 59 alteplase 59 hypercalcemia 58 PRADAXA 58 plus methotrexate 58 TNF α 58 neuroprotective properties 58 APTIVUS 58 pharmacokinetic properties 58 Pegasys ® 58 GFT# 58 events AEs 58 microvascular complications 58 tirofiban 58 fulvestrant 58 trimethoprim sulfamethoxazole 58 tumor lysis syndrome 58 bronchodilation 58 retinal thickness 58 DOXIL 58 fibrinolytic 58 Thrombocytopenia 58 Secondary endpoints include 58 Combination therapy 58 Tolerability 58 Aliskiren 58 Carfilzomib 58 bleomycin 58 mg kg dose 58 bendamustine 58 androgen deprivation 57 achieved statistical significance 57 sustained virologic response 57 febrile neutropenia 57 TYSABRI treated 57 pharmacokinetic PK 57 voriconazole 57 dose regimens 57 concomitant medications 57 cerebrovascular events 57 thromboprophylaxis 57 antiviral activity